FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894626754> ?p ?o ?g. }

• W2894626754 endingPage "83" @default.
• W2894626754 startingPage "75" @default.
• W2894626754 abstract "ABSTRACT Background: Proteases are one of the largest pharmaceutical targets for drug developments. Their dysregulations result in a wide variety of diseases. Because proteolytic networks usually consist of protease family members that share high structural and catalytic homology, distinguishing them using small molecule inhibitors is often challenging. To achieve specific inhibition, this study described a novel approach for the generation of protease inhibitory antibodies. As a proof of concept, we aimed to convert a matrix metalloproteinase (MMP)-14 specific inhibitor to MMP-9 specific inhibitory antibodies with high selectivity. Methods: An error-prone single-chain Fv (scFv) library of an MMP-14 inhibitor 3A2 was generated for yeast surface display. A dual-color competitive FACS was developed for selection on MMP-9 catalytic domain (cdMMP-9) and counter-selection on cdMMP-14 simultaneously, which were fused/conjugated with different fluorophores. Isolated MMP-9 inhibitory scFvs were biochemically characterized by inhibition assays on MMP-2/-9/-12/-14, proteolytic stability tests, inhibition mode determination, competitive ELISA with TIMP-2 (a native inhibitor of MMPs), and paratope mutagenesis assays. Results: We converted an MMP-14 specific inhibitor 3A2 into a panel of MMP-9 specific inhibitory antibodies with dramatic selectivity shifts of 690–4,500 folds. Isolated scFvs inhibited cdMMP-9 at nM potency with high selectivity over MMP-2/-12/-14 and exhibited decent proteolytic stability. Biochemical characterizations revealed that these scFvs were competitive inhibitors binding to cdMMP-9 near its reaction cleft via their CDR-H3s. Conclusions: This study developed a novel approach able to convert the selectivity of inhibitory antibodies among closely related protease family members. This methodology can be directly applied for mAbs inhibiting many proteases of biomedical importance. Statement of Significance To achieve high selectivity required for therapies, we developed a novel approach for the generation of protease inhibitory antibodies with nM potency and decent proteolytic stability. The methodology demonstrated here can be readily applied to many proteases of biomedical importance." @default.
• W2894626754 created "2018-10-12" @default.
• W2894626754 creator A5014515622 @default.
• W2894626754 creator A5020678188 @default.
• W2894626754 creator A5024023393 @default.
• W2894626754 creator A5029271949 @default.
• W2894626754 creator A5060633938 @default.
• W2894626754 creator A5065053888 @default.
• W2894626754 creator A5067846105 @default.
• W2894626754 date "2018-09-01" @default.
• W2894626754 modified "2023-10-10" @default.
• W2894626754 title "Selectivity Conversion of Protease Inhibitory Antibodies" @default.
• W2894626754 cites W1943317391 @default.
• W2894626754 cites W1975489435 @default.
• W2894626754 cites W1990240889 @default.
• W2894626754 cites W1990789777 @default.
• W2894626754 cites W1999879329 @default.
• W2894626754 cites W2005334224 @default.
• W2894626754 cites W2010004352 @default.
• W2894626754 cites W2010666032 @default.
• W2894626754 cites W2010912389 @default.
• W2894626754 cites W2013491297 @default.
• W2894626754 cites W2017871159 @default.
• W2894626754 cites W2019681593 @default.
• W2894626754 cites W2026422955 @default.
• W2894626754 cites W2028768078 @default.
• W2894626754 cites W2036662231 @default.
• W2894626754 cites W2037042031 @default.
• W2894626754 cites W2040856541 @default.
• W2894626754 cites W2046296795 @default.
• W2894626754 cites W2048489629 @default.
• W2894626754 cites W2053687002 @default.
• W2894626754 cites W2055524098 @default.
• W2894626754 cites W2056119618 @default.
• W2894626754 cites W2056511887 @default.
• W2894626754 cites W2062919894 @default.
• W2894626754 cites W2063572236 @default.
• W2894626754 cites W2066306198 @default.
• W2894626754 cites W2074440833 @default.
• W2894626754 cites W2075503331 @default.
• W2894626754 cites W2078337807 @default.
• W2894626754 cites W2097019319 @default.
• W2894626754 cites W2100695350 @default.
• W2894626754 cites W2132164302 @default.
• W2894626754 cites W2136244824 @default.
• W2894626754 cites W2155879201 @default.
• W2894626754 cites W2162498703 @default.
• W2894626754 cites W2169515696 @default.
• W2894626754 cites W2318140151 @default.
• W2894626754 cites W2473135273 @default.
• W2894626754 cites W2510277784 @default.
• W2894626754 cites W2565119563 @default.
• W2894626754 cites W2566447341 @default.
• W2894626754 cites W2575764448 @default.
• W2894626754 cites W2609822108 @default.
• W2894626754 cites W2613448640 @default.
• W2894626754 cites W2754857131 @default.
• W2894626754 cites W2784269733 @default.
• W2894626754 cites W2885742860 @default.
• W2894626754 cites W53165165 @default.
• W2894626754 doi "https://doi.org/10.1093/abt/tby008" @default.
• W2894626754 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7990135" @default.
• W2894626754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30406213" @default.
• W2894626754 hasPublicationYear "2018" @default.
• W2894626754 type Work @default.
• W2894626754 sameAs 2894626754 @default.
• W2894626754 citedByCount "1" @default.
• W2894626754 countsByYear W28946267542020 @default.
• W2894626754 crossrefType "journal-article" @default.
• W2894626754 hasAuthorship W2894626754A5014515622 @default.
• W2894626754 hasAuthorship W2894626754A5020678188 @default.
• W2894626754 hasAuthorship W2894626754A5024023393 @default.
• W2894626754 hasAuthorship W2894626754A5029271949 @default.
• W2894626754 hasAuthorship W2894626754A5060633938 @default.
• W2894626754 hasAuthorship W2894626754A5065053888 @default.
• W2894626754 hasAuthorship W2894626754A5067846105 @default.
• W2894626754 hasBestOaLocation W28946267541 @default.
• W2894626754 hasConcept C104317684 @default.
• W2894626754 hasConcept C109523444 @default.
• W2894626754 hasConcept C150757390 @default.
• W2894626754 hasConcept C153911025 @default.
• W2894626754 hasConcept C159654299 @default.
• W2894626754 hasConcept C167625842 @default.
• W2894626754 hasConcept C169760540 @default.
• W2894626754 hasConcept C17077164 @default.
• W2894626754 hasConcept C181199279 @default.
• W2894626754 hasConcept C182220744 @default.
• W2894626754 hasConcept C185592680 @default.
• W2894626754 hasConcept C186268636 @default.
• W2894626754 hasConcept C2776471321 @default.
• W2894626754 hasConcept C2776714187 @default.
• W2894626754 hasConcept C2779281246 @default.
• W2894626754 hasConcept C542903549 @default.
• W2894626754 hasConcept C54355233 @default.
• W2894626754 hasConcept C55493867 @default.
• W2894626754 hasConcept C86803240 @default.
• W2894626754 hasConcept C9086966 @default.
• W2894626754 hasConceptScore W2894626754C104317684 @default.

• next